Once-Monthly Continuous Erythropoietin Receptor Activator (C.E.R.A.) in Patients with Hemodialysis-Dependent Chronic Kidney Disease: Pooled Data from Phase III Trials

Francesco Locatelli, Gabriel Choukroun, Matt Truman, Alfons Wiggenhauser, Danilo Fliser, Francesco Locatelli, Gabriel Choukroun, Matt Truman, Alfons Wiggenhauser, Danilo Fliser

Abstract

Introduction: Erythropoiesis-stimulating agents and iron are commonly used in patients with chronic kidney disease with the aim of correcting anemia and maintaining stable hemoglobin levels. We analyzed pooled data from 13 studies with similar designs included in the Umbrella Continuous Erythropoietin Receptor Activator (C.E.R.A.) program to investigate the effects of continuous erythropoiesis receptor activator in clinically relevant subgroups of patients with chronic kidney disease and to determine whether the efficacy and safety outcomes demonstrated in the overall chronic kidney disease population are maintained in specific subgroups.

Methods: Data from 13 Phase III trials set up with similar design were retrospectively pooled for this analysis. Patients with chronic kidney disease who had previously been receiving epoetin or darbepoetin were switched to continuous erythropoiesis receptor activator once-monthly after a 4- to 8-week screening period. Patients entered a 16-week continuous erythropoiesis receptor activator dose-titration period followed by an 8-week evaluation period. In total, 2060 patients were included in the analysis. Subgroups were defined based on: hemoglobin target range [lower (10.0-12.0 g/dL)/upper (10.5-13.0 g/dL)], gender (female/male), age (<65/≥65), baseline N-terminal pro-B-type natriuretic peptide levels (<5000/≥5000), cardiovascular risk factors (diabetes/cardiac/vascular/none).

Results: Across all subgroups analyzed, switching from shorter-acting erythropoiesis-stimulating agents to continuous erythropoiesis receptor activator once-monthly maintained stable hemoglobin concentrations in a high proportion of patients (78%), with only moderate hemoglobin fluctuations and a low number of dose changes. The safety profile across subgroups was as expected based on pre-existing risk factors; observed increases in adverse events were attributable to underlying risk factors rather than study drug.

Conclusions: This retrospective analysis of 13 trials showed that continuous erythropoiesis receptor activator once-monthly maintained stable hemoglobin levels across a number of clinically relevant patient subgroups, including those with higher inherent cardiovascular risk. The safety profile was consistent with that previously established in the chronic kidney disease population. CLINICALTRIALS.

Gov identifiers: NCT00413894/NCT00545571/NCT00517413/NCT00560404/NCT00882713/NCT00550680/NCT00576303/NCT00660023/NCT00717821/NCT00642850/NCT00605293/NCT00661505/NCT00699348.

Funding: F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Keywords: Anemia, chronic kidney disease; Continuous erythropoiesis; Efficacy; Hemodialysis; Patient subgroups; Pooled analysis; Receptor activator.

Figures

Fig. 1
Fig. 1
Common study design. In all 13 studies, enrolled patients entered a 4- to 8-week screening period followed by a 16-week C.E.R.A. dose-titration period, and an 8-week evaluation period. C.E.R.A. continuous erythropoietin receptor activator, ESA erythropoiesis-stimulating agents
Fig. 2
Fig. 2
Proportion of patients exhibiting hemoglobin stability. Across all studied subgroups, a large majority of patients (76–80%) exhibited hemoglobin stability (hemoglobin concentration within ±1 g/dL from screening or within the target range, evaluation period). CV cardiovascular, L lower, NT-proBNP N-terminal pro-B-type natriuretic peptide, U upper
Fig. 3
Fig. 3
Mean Hb levels over time, by target Hb group. The error bars show 95% confidence intervals. In the upper (square symbols) and the lower (triangle symbols) Hb target groups, the achieved Hb levels were stable over time. Hb hemoglobin
Fig. 4
Fig. 4
Percentage of patients with CV AEs per dose, Hb and CRP quintile. The proportion of patients experiencing cardiac, serious CV, thromboembolic, and vascular AEs is shown by quintiles of Hb, C.E.R.A. dose and CRP. AE adverse event, C.E.R.A. continuous erythropoietin receptor activator, CRP C-reactive protein, CV cardiovascular, Hb hemoglobin

References

    1. Portoles J, Gorriz JL, Rubio E, de Alvaro F, Garcia F, Alvarez-Chivas V, et al. The development of anemia is associated to poor prognosis in NKF/KDOQI stage 3 chronic kidney disease. BMC Nephrol. 2013;14:2. doi: 10.1186/1471-2369-14-2.
    1. Kovesdy CP, Trivedi BK, Kalantar-Zadeh K, Anderson JE. Association of anemia with outcomes in men with moderate and severe chronic kidney disease. Kidney Int. 2006;69:560–564. doi: 10.1038/sj.ki.5000105.
    1. Locatelli F, Covic A, Eckardt KU, Wiecek A, Vanholder R. Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP) Nephrol Dial Transpl. 2009;24:348–354. doi: 10.1093/ndt/gfn653.
    1. Locatelli F, Del Vecchio L. An expert opinion on the current treatment of anemia in patients with kidney disease. Expert Opin Pharmacother. 2012;13:495–503. doi: 10.1517/14656566.2012.658369.
    1. Palmer SC, Saglimbene V, Mavridis D, Salanti G, Craig JC, Tonelli M, et al. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database Syst Rev. 2014;12:CD010590.
    1. Macdougall IC, Robson R, Opatrna S, Liogier X, Pannier A, Jordan P, et al. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2006;1:1211–1215. doi: 10.2215/CJN.00730306.
    1. Locatelli F, Villa G, de Francisco AL, Albertazzi A, Adrogue HJ, Dougherty FC, et al. Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administration. Curr Med Res Opin. 2007;23:969–979. doi: 10.1185/030079907X182103.
    1. Levin NW, Fishbane S, Canedo FV, Zeig S, Nassar GM, Moran JE, et al. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA) Lancet. 2007;370:1415–1421. doi: 10.1016/S0140-6736(07)61599-2.
    1. Sulowicz W, Locatelli F, Ryckelynck JP, Balla J, Csiky B, Harris K, et al. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol. 2007;2:637–646. doi: 10.2215/CJN.03631006.
    1. Dellanna F, Winkler RE, Bozkurt F, Schettler V, Graf S, Bockreiss N, et al. Dosing strategies for conversion of haemodialysis patients from short-acting erythropoiesis stimulating agents to once-monthly C.E.R.A.: experience from the MIRACEL study. Int J Clin Pract. 2011;65:64–72. doi: 10.1111/j.1742-1241.2010.02551.x.
    1. Weinreich T, Leistikow F, Hartmann HG, Vollgraf G, Dellanna F. Monthly continuous erythropoietin receptor activator treatment maintains stable hemoglobin levels in routine clinical management of hemodialysis patients. Hemodial Int. 2012;16:11–19. doi: 10.1111/j.1542-4758.2011.00608.x.
    1. Fliser D, Kleophas W, Dellanna F, Winkler RE, Backs W, Kraatz U, et al. Evaluation of maintenance of stable haemoglobin levels in haemodialysis patients converting from epoetin or darbepoetin to monthly intravenous C.E.R.A.: the MIRACEL study. Curr Med Res Opin. 2010;26:1083–1089. doi: 10.1185/03007991003666652.
    1. Mann JF, de Francisco A, Nassar G, Canaud B. Fewer dose changes with once-monthly C.E.R.A. in patients with chronic kidney disease. Clin Nephrol. 2011;76:9–15. doi: 10.5414/CN106847.
    1. Carrera F, Lok CE, de Francisco A, Locatelli F, Mann JF, Canaud B, et al. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrol Dial Transpl. 2010;25:4009–4017. doi: 10.1093/ndt/gfq305.
    1. Bastos K, Lucarelli LA, De Francesco-Daher E, Filho RP, Henriquez C, Espinoza B, et al. C.E.R.A. maintains stable hemoglobin in Latin American patients on dialysis. Int Urol Nephrol. 2012;45:1355–1364. doi: 10.1007/s11255-012-0272-3.
    1. Chen N, Qian JQ, Mei CL, Zhang AH, Xing CY, Wang L, et al. The efficacy and safety of continuous erythropoietin receptor activator in dialytic patients with chronic renal anemia: an open, randomized, controlled, multi-center trial. Zhonghua Nei Ke Za Zhi. 2012;51:502–507.
    1. Dellanna F, Dickenmann M, Shilo V, Kleophas W. Prognostic value of N-terminal Pro-B-type natriuretic peptide (NT-proBNP) concentrations in patients with end stage renal disease. Proceedings of Kidney Week; 2012 Oct 30–Nov 4; San Diego, CA, USA. American Society of Nephrology; 2012.
    1. European Medicines Agency: Mircera Summary of Product Characteristics. 2009 [updated 07/10/2014; cited 04/03/15]. . Accessed 4 Mar 2015.
    1. Locatelli F, Dusilova-Sulkova S. Characteristics of patients with chronic kidney disease on dialysis with a poor response to continuous erythropoietin receptor activator (C.E.R.A.) once monthly: an analysis of 10 international trials. Nephrol Dial Transpl. 2012;27(suppl 2):ii133–ii145.
    1. Fliser D, Shilo V. Continuous erythropoietin receptor activator (C.E.R.A.) once monthly maintains stable hemoglobin values in high-risk patients with chronic kidney disease on dialysis: an analysis of 10 international trials. Nephrol Dial Transpl. 2012;27(suppl 2):ii133–ii145.
    1. Locatelli F, Mann JF, Aldigier JC, Sanz Guajardo D, Schmidt R, Van Vlem B, et al. C.E.R.A. safety profile: a pooled analysis in patients with chronic kidney disease. Clin Nephrol. 2010;73:94–103. doi: 10.5414/CNP73094.
    1. Locatelli F, Choukroun G, Fliser D, Moecks J, Wiggenhauser A. Dosing of continuous erythropoietin receptor activator (C.E.R.A.) once monthly vs darbepoetin, epoetin alfa or epoetin beta in high-risk patients with chronic kidney disease on dialysis: an analysis of 13 international trials Nephrol Dial Transpl. 2014:29(Suppl 3):iii491–iii500.
    1. Locatelli F, de Francisco A, Deray G, Fliser D, Armstrong G, Dougherty FC, et al. Mortality and cardiovascular morbidity associated with haemoglobin levels: a pooled analysis of randomised controlled trials. Nephron Clin Pract. 2014;128:323–332. doi: 10.1159/000366478.
    1. Locatelli F, Altieri P, Andrulli S, Sau G, Bolasco P, Pedrini LA, et al. Predictors of haemoglobin levels and resistance to erythropoiesis-stimulating agents in patients treated with low-flux haemodialysis, haemofiltration and haemodiafiltration: results of a multicentre randomized and controlled trial. Nephrol Dial Transpl. 2012;27:3594–3600. doi: 10.1093/ndt/gfs117.
    1. Locatelli F, Hannedouche T, Martin-Malo A, Jacobson SH, Vanholder R, Ronco C, et al. The relationship of NT-proBNP and dialysis parameters with outcome of incident haemodialysis patients: results from the membrane permeability outcome study. Blood Purif. 2013;35:216–223. doi: 10.1159/000347076.
    1. Locatelli F, Barany P, Covic A, De Francisco A, Del Vecchio L, Goldsmith D, et al. Kidney disease: improving global outcomes guidelines on anaemia management in chronic kidney disease: a european renal best practice position statement. Nephrol Dial Transpl. 2013;28:1346–1359. doi: 10.1093/ndt/gft033.
    1. Lagrand WK, Visser CA, Hermens WT, Niessen HW, Verheugt FW, Wolbink GJ, et al. C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation. 1999;100:96–102. doi: 10.1161/01.CIR.100.1.96.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅